<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>NurExone</title>
	<atom:link href="https://nurexone.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://nurexone.com/</link>
	<description>From acute injury to functional recovery</description>
	<lastBuildDate>Sun, 01 Nov 2026 10:35:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://nurexone.com/wp-content/uploads/2024/02/NurExone-Logo-Rebrand-icon-copy-150x150.webp</url>
	<title>NurExone</title>
	<link>https://nurexone.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes</title>
		<link>https://nurexone.com/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes/</link>
					<comments>https://nurexone.com/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Fri, 30 Oct 2026 10:33:22 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://nurexone.com/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes/</guid>

					<description><![CDATA[<p>TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory results demonstrating consistent anti-inflammatory activity across three batches of its naïve exosomes, supporting both its developing commercial supply business through Exo-Top Inc. (“Exo-Top”) and continued development of its [&#8230;]</p>
<p>The post <a href="https://nurexone.com/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes/">NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p align="justify">TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory results demonstrating consistent anti-inflammatory activity across three batches of its naïve exosomes, supporting both its developing commercial supply business through Exo-Top Inc. (“Exo-Top”) and continued development of its lead therapeutic candidate, ExoPTEN.</p>
<p align="justify">Anti-inflammatory activity is a key biological property attracting interest in exosomes for applications ranging from skin health to tissue repair. NurExone&#8217;s latest results showed that three separately produced batches demonstrated similar and substantial anti-inflammatory activity. Two key proteins involved in inflammation, IL-6 and TNF-α, showed average reductions of approximately 88% and 57%, respectively. This anti-inflammatory activity shown in the laboratory supports the potential of NurExone&#8217;s exosomes for clinical applications where controlling inflammation is relevant to tissue protection, repair and regeneration.</p>
<p align="justify">“The anti-inflammatory properties of our exosomes have potential relevance for both our therapeutic development and commercial strategy,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “For ExoPTEN, these findings support the exosome component of our approach to acute spinal cord and optic nerve injuries. For Exo-Top, they provide additional evidence of product consistency as we begin manufacturing and work toward supplying naïve exosomes for applications such as skin and tissue care. Addressing batch-to-batch consistency, a critical unmet challenge in the exosome field, helps distinguish the quality and reliability we expect to bring to the exosome market.”</p>
<p align="justify"><strong><a href="https://www.globenewswire.com/news-release/2026/10/30/3392203/0/en/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes.html" target="_blank" rel="noopener">READ MORE &gt;&gt;</a></strong></p>
<p>The post <a href="https://nurexone.com/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes/">NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/nurexone-demonstrates-consistent-anti-inflammatory-activity-across-three-separate-batches-of-exosomes/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>How NurExone Biologic Advances Regenerative Nanodrugs for CNS Injuries Led by Dr. Lior Shaltiel</title>
		<link>https://nurexone.com/how-nurexone-biologic-advances-regenerative-nanodrugs-for-cns-injuries-led-by-dr-lior-shaltiel/</link>
					<comments>https://nurexone.com/how-nurexone-biologic-advances-regenerative-nanodrugs-for-cns-injuries-led-by-dr-lior-shaltiel/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Sun, 25 Oct 2026 15:06:08 +0000</pubDate>
				<category><![CDATA[In The Media]]></category>
		<guid isPermaLink="false">https://nurexone.com/the-most-innovative-regenerative-medicine-company-to-watch/</guid>

					<description><![CDATA[<p>In central nervous system injuries, diagnosis and immediate stabilization rarely define the long-term challenge. Recovery does. The adult CNS has a very limited ability to repair itself. Most current treatments focus on managing symptoms instead of restoring lost function. As a result, many patients adapt to permanent impairments rather than regain independence. This gap between [&#8230;]</p>
<p>The post <a href="https://nurexone.com/how-nurexone-biologic-advances-regenerative-nanodrugs-for-cns-injuries-led-by-dr-lior-shaltiel/">How NurExone Biologic Advances Regenerative Nanodrugs for CNS Injuries Led by Dr. Lior Shaltiel</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p style="text-align: left;">In central nervous system injuries, diagnosis and immediate stabilization rarely define the long-term challenge. Recovery does. The adult CNS has a very limited ability to repair itself.</p>
<p style="text-align: left;">Most current treatments focus on managing symptoms instead of restoring lost function. As a result, many patients adapt to permanent impairments rather than regain independence. This gap between survival and real functional recovery remains one of the most urgent problems in modern medicine. Closing it requires more than incremental improvements. It demands therapies that actively support regeneration and restore function.</p>
<div style="text-align: left;">
<div role="feed" aria-label="Chat messages" aria-describedby="_r_8f_">
<div aria-hidden="true"><a href="https://theelitesuccess.com/the-most-innovative-regenerative-medicine-company-to-watch/" target="_blank" rel="noopener"><strong>Raed More &gt;&gt;&gt;</strong></a></div>
</div>
<div>
<div></div>
<div>
<div>
<div>
<div></div>
</div>
</div>
</div>
</div>
<div aria-hidden="true"></div>
</div>
<div style="text-align: left;" aria-hidden="true"></div>
<p>The post <a href="https://nurexone.com/how-nurexone-biologic-advances-regenerative-nanodrugs-for-cns-injuries-led-by-dr-lior-shaltiel/">How NurExone Biologic Advances Regenerative Nanodrugs for CNS Injuries Led by Dr. Lior Shaltiel</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/how-nurexone-biologic-advances-regenerative-nanodrugs-for-cns-injuries-led-by-dr-lior-shaltiel/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale</title>
		<link>https://nurexone.com/exosomes-move-toward-the-mainstream-manufacturing-may-be-the-key-to-scale/</link>
					<comments>https://nurexone.com/exosomes-move-toward-the-mainstream-manufacturing-may-be-the-key-to-scale/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Sun, 25 Oct 2026 14:43:45 +0000</pubDate>
				<category><![CDATA[In The Media]]></category>
		<guid isPermaLink="false">https://nurexone.com/exosomes-move-toward-the-mainstream-manufacturing-may-be-the-key-to-scale/</guid>

					<description><![CDATA[<p>For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as extracellular vesicle (EV) research moves steadily from basic biology toward therapeutic development, commercial exosome manufacturing and broader applications. [&#8230;]</p>
<p>The post <a href="https://nurexone.com/exosomes-move-toward-the-mainstream-manufacturing-may-be-the-key-to-scale/">Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as extracellular vesicle (EV) research moves steadily from basic biology toward therapeutic development, commercial exosome manufacturing and broader applications.</p>
<p>Exosomes are small extracellular vesicles released by cells and involved in intercellular communication. They contain proteins, lipids and nucleic acids, and their composition reflects both their cellular origin and the biological conditions under which they are produced. These properties have made them attractive for a range of applications, particularly as potential therapeutic delivery vehicles and as biologically active components of regenerative products. They can also be engineered or loaded with defined therapeutic cargo, including RNA-based molecules.</p>
<p>&nbsp;</p>
<p><strong>READ MORE &gt;&gt;&gt;</strong></p>
<p>The post <a href="https://nurexone.com/exosomes-move-toward-the-mainstream-manufacturing-may-be-the-key-to-scale/">Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/exosomes-move-toward-the-mainstream-manufacturing-may-be-the-key-to-scale/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth</title>
		<link>https://nurexone.com/modular-manufacturing-strategy-and-commercial-growth/</link>
					<comments>https://nurexone.com/modular-manufacturing-strategy-and-commercial-growth/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Thu, 22 Oct 2026 15:13:09 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://nurexone.com/modular-manufacturing-strategy-and-commercial-growth/</guid>

					<description><![CDATA[<p>TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced that it doubled exosome production by successfully operating two bioreactors in parallel, while maintaining the same overall production [&#8230;]</p>
<p>The post <a href="https://nurexone.com/modular-manufacturing-strategy-and-commercial-growth/">NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p align="justify">TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced that it doubled exosome production by successfully operating two bioreactors in parallel, while maintaining the same overall production time, process consistency and comparable exosome quality.   The achievement marks an important step in NurExone’s strategy to build scalable exosome manufacturing capabilities through its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), and its manufacturing collaboration with Made Scientific.</p>
<p align="justify">NurExone is pursuing a modular approach that enables manufacturing capacity to expand by adding standardized production units in parallel (scaling out approach), rather than engineering larger bioreactor vessels (scaling up approach). This strategy has the potential to protect capital investments, accelerate development timelines, and allow production to match commercial demand, subject to successful validation and implementation.</p>
<p align="justify"><a href="https://www.globenewswire.com/news-release/2026/10/22/3386349/0/en/nurexone-demonstrates-scalable-exosome-production-supporting-its-modular-manufacturing-strategy-and-commercial-growth.html" target="_blank" rel="noopener"><strong>READ MORE &gt;&gt;&gt;</strong></a></p>
<p>The post <a href="https://nurexone.com/modular-manufacturing-strategy-and-commercial-growth/">NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/modular-manufacturing-strategy-and-commercial-growth/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results</title>
		<link>https://nurexone.com/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results/</link>
					<comments>https://nurexone.com/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 14:55:19 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://nurexone.com/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results/</guid>

					<description><![CDATA[<p>Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its [&#8230;]</p>
<p>The post <a href="https://nurexone.com/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results/">NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p class="article-sub-headline">Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate</p>
<p>TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes (exosomes without added therapeutic cargo) and lead pharmaceutical drug candidate ExoPTEN in optic nerve injury models. The studies were conducted in collaboration with Prof. Ygal Rotenstreich’s team at the Goldschleger Eye Institute at Sheba Medical Center. The new data supports the advancement of the Company’s optic nerve injury program into larger-animal studies, including a planned rabbit model, marking a key milestone toward potential human clinical evaluation.</p>
<p>&nbsp;</p>
<p><a href="https://www.globenewswire.com/news-release/2026/10/09/3378353/0/en/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results.html" target="_blank" rel="noopener"><strong>READ MORE &gt;&gt;&gt;</strong></a></p>
<p>The post <a href="https://nurexone.com/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results/">NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/nurexone-advances-optic-nerve-injury-program-toward-larger-animal-study-following-positive-preclinical-results/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update</title>
		<link>https://nurexone.com/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update/</link>
					<comments>https://nurexone.com/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Fri, 18 Sep 2026 12:23:25 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://nurexone.com/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update/</guid>

					<description><![CDATA[<p>TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from September 22-25, 2026. The conferences will feature [&#8230;]</p>
<p>The post <a href="https://nurexone.com/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update/">NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p align="justify">TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from September 22-25, 2026. The conferences will feature participants from across the global life sciences sector, including investors, scientists and representatives from leading pharmaceutical companies.</p>
<p align="justify">As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively participate as speaker in three conference programs and attend the invitation-only World Medical Innovation Forum. R&amp;D Director Dr. Tali Kizhner will also represent the Company as a speaker at the 8<sup>th</sup> Exosome-Based Therapeutics Development Summit.</p>
<p align="justify"><a href="https://www.globenewswire.com/news-release/2026/09/18/3364949/0/en/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update.html" target="_blank" rel="noopener"><strong>READ MORE &gt;&gt;&gt;</strong></a></p>
<p>The post <a href="https://nurexone.com/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update/">NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/nurexone-expands-u-s-engagement-across-four-major-boston-life-sciences-events-and-provides-corporate-update/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update</title>
		<link>https://nurexone.com/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update/</link>
					<comments>https://nurexone.com/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Wed, 16 Sep 2026 12:53:29 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://nurexone.com/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update/</guid>

					<description><![CDATA[<p>TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, September [&#8230;]</p>
<p>The post <a href="https://nurexone.com/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update/">NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p align="justify">TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“<strong>Shareholders</strong>”) held on Tuesday, September 15, 2026 (the “<strong>Meeting</strong>”). Shareholders voted in favour of each resolution put forth at the Meeting.</p>
<p align="justify"><strong>Annual General and Special Meeting Results</strong></p>
<p align="justify">Capitalized terms used but not otherwise defined in this press release have the meanings ascribed to them in the Company’s management information circular dated August 10, 2026 (the “<strong>Circular</strong>”). Additional information regarding the Consolidation is contained in the Circular and the Company’s press release dated August 21, 2026.</p>
<p align="justify"><a href="https://www.globenewswire.com/news-release/2026/09/16/3363531/0/en/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update.html" target="_blank" rel="noopener"><strong>READ MORE &gt;&gt;&gt;</strong></a></p>
<p>The post <a href="https://nurexone.com/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update/">NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/nurexone-announces-voting-results-of-annual-general-and-special-meeting-of-shareholders-and-provides-corporate-update/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications</title>
		<link>https://nurexone.com/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications/</link>
					<comments>https://nurexone.com/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Mon, 14 Sep 2026 15:26:38 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://nurexone.com/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications/</guid>

					<description><![CDATA[<p>TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPass Technologies Ltd. (“NanoPass”), a medical device [&#8230;]</p>
<p>The post <a href="https://nurexone.com/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications/">NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p align="justify">TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “<strong>MOU</strong>”) with NanoPass Technologies Ltd. (“NanoPass”), a medical device company specializing in precision delivery, to evaluate the integration of NanoPass’s MicronJet™ platform with NurExone’s exosome formulations for eye and skin applications.</p>
<p align="justify">NurExone’s exosomes are designed to act as biological delivery vehicles, targeting damaged tissue either on their own or carrying therapeutic cargo. NanoPass’s FDA-cleared MicronJet™ intradermal delivery platform provides precise, controlled and safe placement at the site of administration (leveraging advanced MEMS technology silicon-crystal pyramids).</p>
<p align="justify"><a href="https://www.globenewswire.com/news-release/2026/09/14/3361533/0/en/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications.html" target="_blank" rel="noopener"><strong>READ MORE &gt;&gt;&gt;</strong></a></p>
<p>The post <a href="https://nurexone.com/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications/">NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/nurexone-and-nanopass-technologies-ltd-to-collaborate-on-integrated-exosome-delivery-approach-for-regenerative-eye-and-skin-applications/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>2026 Disruptive Growth &#038; Life Sciences Conference</title>
		<link>https://nurexone.com/2026-disruptive-growth-life-sciences-conference/</link>
					<comments>https://nurexone.com/2026-disruptive-growth-life-sciences-conference/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Wed, 02 Sep 2026 14:27:42 +0000</pubDate>
				<category><![CDATA[Coming Events]]></category>
		<category><![CDATA[Events]]></category>
		<guid isPermaLink="false">https://nurexone.com/2026-disruptive-growth-life-sciences-conference/</guid>

					<description><![CDATA[<p>The post <a href="https://nurexone.com/2026-disruptive-growth-life-sciences-conference/">2026 Disruptive Growth &#038; Life Sciences Conference</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://nurexone.com/2026-disruptive-growth-life-sciences-conference/">2026 Disruptive Growth &#038; Life Sciences Conference</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/2026-disruptive-growth-life-sciences-conference/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results</title>
		<link>https://nurexone.com/nurexone-biologic-inc-announces-second-quarter-2026-financial-results/</link>
					<comments>https://nurexone.com/nurexone-biologic-inc-announces-second-quarter-2026-financial-results/#respond</comments>
		
		<dc:creator><![CDATA[Nurexone]]></dc:creator>
		<pubDate>Mon, 31 Aug 2026 14:08:37 +0000</pubDate>
				<category><![CDATA[Press Releases]]></category>
		<guid isPermaLink="false">https://nurexone.com/nurexone-biologic-inc-announces-second-quarter-2026-financial-results/</guid>

					<description><![CDATA[<p>TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) &#8212; NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce its financial results for the second quarter ended June 30, 2026 (“Q2”), and to provide a corporate update on its recent activities and [&#8230;]</p>
<p>The post <a href="https://nurexone.com/nurexone-biologic-inc-announces-second-quarter-2026-financial-results/">NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p align="justify">TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) &#8212; <strong>NurExone Biologic Inc. </strong>(TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce its financial results for the second quarter ended June 30, 2026 (“<strong>Q2</strong>”), and to provide a corporate update on its recent activities and upcoming milestones.</p>
<p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a title="www.nurexone.com" href="https://www.globenewswire.com/Tracker?data=epn--lrNAVyjP4jUABv7CwWWFqV7P0U_zMX-9QZLt6MklKqfakMOQ1fjULwdmnVuYPluBspNXce47Qmlxw_W33hpO7PnJgtBJdXe3uR_LSplR3A8Li6Of3E_d3Cmlbe0B04Llv1fhQnWZaMlVvKWwRfTfWoo_Ggyd9P6482nzHuNv6hX_hefgyQCbqEgwal-pmi1l_ZC9Kx8SM8jyWu1ysdac3_vaxzRV9EUoNKdyn2434h-OZ8mdqtkUwGCi8vsw12-c2A3-BPYlZl-9kGXVcAmfJEa3_D3y5brFuBhyQxo7HActfAliTeAu1kO8p9dwqPYqkJ04rXKKLXA33r5G9D3haZsrUMvCwhgWhoItzzO57bkJr8JlFzgTz2kz05zsszeFkk5v5KeQfUzad4eCTpb5fUELA86X7JZ8qhLPKQNqN_ZFGnVRyPAtSY98juegcRx63O1RJ64xEb4nOEj0k87u_aV6xkzc6eEriXMHzM=" target="_blank" rel="nofollow noopener">www.nurexone.com</a> and its SEDAR+ profile at <a title="www.sedarplus.ca." href="https://www.globenewswire.com/Tracker?data=KHuQm9VX1E9GJOERTmU0pZZZL-GQWmnr5yOFdlqeRSsszpW4IrxmLWJqqocxZx7JOt9F-qi62PTQFcIduZU0eK7Q5m5B_4Fkx6Wd7_q6-OrUW5xELY81WvqKNbdlMbd6d5zGCHLnJNiE4brcVh7rfFJ8mYwbQc44m9XWCiCmn9YuouF-wShrEmfTrXZxWplnMuXfgZ-785TpG1euyWa4WtFNgdBW7E6EHx9Q7htbx8UD2mQUSY4VUB_5wWoawTZhdDgqUWtsVDm371ENbM1c4w==" target="_blank" rel="nofollow noopener">www.sedarplus.ca.</a></p>
<p align="justify"><a href="https://www.globenewswire.com/news-release/2026/08/31/3353218/0/en/nurexone-biologic-inc-announces-second-quarter-2026-financial-results.html" target="_blank" rel="noopener"><strong>READ MORE &gt;&gt;&gt;</strong></a></p>
<p>The post <a href="https://nurexone.com/nurexone-biologic-inc-announces-second-quarter-2026-financial-results/">NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results</a> appeared first on <a href="https://nurexone.com">NurExone</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://nurexone.com/nurexone-biologic-inc-announces-second-quarter-2026-financial-results/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
